ID | 111999 |
Title Alternative | A radioprotective agonist for p53 transactivation
|
Author |
Morita, Akinori
Hiroshima University|Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Takahashi, Ippei
Hiroshima University
Sasatani, Megumi
Hiroshima University
Aoki, Shin
Tokyo University of Science
Wang, Bing
National Institutes for Quantum and Radiological Science and Technology
Ariyasu, Shinya
Tokyo University of Science
Tanaka, Kaoru
National Institutes for Quantum and Radiological Science and Technology
Yamaguchi, Tetsuji
Hiroshima University
Sawa, Akiko
Tokyo University of Science
Nishi, Yurie
Tokyo University of Science
Teraoka, Tatsuro
Tokyo University of Science
Ujita, Shohei
Tokushima University
Kawate, Yosuke
Tokushima University
Yanagawa, Chihiro
Tokushima University
Tanimoto, Keiji
Hiroshima University
Enomoto, Atsushi
The University of Tokyo
Nenoi, Mitsuru
National Institutes for Quantum and Radiological Science and Technology
Kamiya, Kenji
Hiroshima University
Nagata, Yasushi
Hiroshima University
Hosoi, Yoshio
Hiroshima University|Tohoku University
Inaba, Toshiya
Hiroshima University
|
Keywords | p53
p21
radioprotector
apoptosis
cell death
gastrointestinal syndrome
|
Content Type |
Journal Article
|
Description | Inhibiting p53-dependent apoptosis by inhibitors of p53 is an effective strategy for preventing radiation-induced damage in hematopoietic lineages, while p53 and p21 also play radioprotective roles in the gastrointestinal epithelium. We previously identified some zinc(II) chelators, including 8-quinolinol derivatives that suppress apoptosis in attempts to discover compounds that target the zinc-binding site in p53. We found that 5-chloro-8-quinolinol (5CHQ) has a unique p53-modulating activity that shifts its transactivation from proapoptotic to protective responses including enhancing p21 induction and suppressing PUMA induction. This p53-modulating activity also influenced p53 and p53-target gene expression in unirradiated cells without inducing DNA damage. The specificity of 5CHQ for p53 and p21 was demonstrated by silencing the expression of each protein. These effects seems to be attributable to the sequence-specific alteration of p53 DNA-binding, as evaluated by chromatin immunoprecipitation and electrophoretic mobility shift assays. In addition, 5-chloro-8-methoxyquinoline itself had no antiapoptotic activity, indicating that the hydroxyl group at the 8-position is required for its antiapoptotic activity. We applied this remarkable agonistic activity to protecting the hematopoietic and gastrointestinal system in mouse irradiation models. The dose-reduction factors of 5CHQ in total-body and abdominally irradiated mice were about 1.2 and 1.3, respectively. 5CHQ effectively protected mouse epithelial stem cells from a lethal dose of abdominal irradiation. Furthermore, the specificity of 5CHQ for p53 in reducing the lethality induced by abdominal irradiation was revealed in Trp53-KO mice. These results indicate that the pharmacological upregulation of radioprotective p53-target genes is an effective strategy for addressing the gastrointestinal syndrome.
|
Journal Title |
Molecular Cancer Therapeutics
|
ISSN | 15357163
15388514
|
NCID | AA11481959
AA12005007
|
Publisher | The American Association for Cancer Research, Inc.
|
Volume | 17
|
Issue | 2
|
Start Page | 432
|
End Page | 442
|
Published Date | 2018-02
|
Rights | ©2017 American Association for Cancer Research.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Author
|
departments |
Medical Sciences
|